The global ulcerative colitis treatment market was valued at around US$ 6.6 Billion at the end of 2021. The market is projected to register a 6.0% CAGR and top a valuation of US$ 11.8 Billion by 2032.
“The principal aspects influencing the market growth are the wide prevalence of UC disease and the growing awareness of the various treatment options.”
Inflammatory bowel disease (IBD) also known as ulcerative colitis (UC) affects the digestive tract and results in irritation, inflammation, and sores. It typically affects the rectum and large intestine (or colon) inner lining. The signs and symptoms of UC usually appear gradually, and those who have been diagnosed with the condition may occasionally have minor or no symptoms. It may, however, occasionally result in serious or even fatal consequences. Even though there is currently no cure for UC, medication can assist patients in managing and reducing their symptoms, avoiding flare-ups, and achieving long-term remission.
| Attributes | Details |
|---|---|
| Ulcerative Colitis Treatment Market Value in 2021 | US$ 6.6 Billion |
| Ulcerative Colitis Treatment Market Value in 2032 | US$ 11.8 Billion |
| Ulcerative Colitis Treatment Market CAGR (2022 to 2032) | 6.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to reports, increasingly industrializing nations in Eastern Europe, South America, Africa, and Asia are experiencing a sharp increase in the number of new cases of UC. The greater prevalence of UC in developing nations compared to industrialized nations is mostly due to factors such as increased use of antibiotics, westernized eating habits, higher exposure to pollutants, and improvements in hygiene.
The market is expanding due to aspects such as the rising prevalence of ulcerative colitis, the expansion of patient assistance programs, technological developments, and more research. The most prevalent type of inflammatory bowel disease, known as ulcerative colitis (UC), affects many people. According to a study published in June 2022, there are 9 to 20 cases of ulcerative colitis worldwide per lakh population each year. Between 156 and 291 cases per lakh population are reported annually. Adults are more likely to suffer from ulcerative colitis. The industry is anticipated to develop due to the high burden of disease.
The ulcerative colitis treatment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America is the leading region in the global ulcerative colitis treatment market owing to the rise in a number of ulcerative colitis diseases and the presence of key players.
The European ulcerative colitis treatment market is also expected to display lucrative growth in the projected years due more aware populace and increased healthcare spending.
The East Asian region is predicted to show lucrative growth owing to the increasing prevalence of inflammatory bowel disease and expanding healthcare infrastructure.
Principal Consultant
Johnson and Johnson, AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., Abbott Laboratories, AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline Plc., Pfizer Inc., Ajinomoto CO. INC.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 6.0% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Type, Disease Type, Drug Class, Molecule Type, Route of Administration, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Johnson and Johnson; AbbVie Inc. (Allergan, Inc.); Merck & Co., Inc.; Novartis AG; Bausch Health Companies Inc.; Abbott Laboratories; AstraZeneca; Eli Lilly; Sanofi; GlaxoSmithKline Plc.; Pfizer Inc.; Ajinomoto CO. INC. |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global ulcerative colitis treatment market is anticipated to register a CAGR of 6.0% during the forecast period.
The global ulcerative colitis treatment market is projected to be about US$ 11.8 Billion by the end of the year 2032.
Explore Healthcare Insights
View Reports
Ulcerative Colitis Treatment Market
